Close Menu

Nobel Prize-winning scientist Paul Greengard has discovered a new way for researchers to target Alzheimer's disease. Beta amyloid, the plaque that builds up in the brains of Alzheimer's patients, has long been targeted by researchers. Now Greengard has discovered a new protein that is needed to make beta amyloid, reports the New York Times' Gina Kolata. Many Alzheimer's drugs currently being studied target the enzyme gamma secretase, which helps make beta amyloid.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.